STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer

STAT PlusHealth At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer Manage alerts for this article Email this article Share this article By Adam Feuerstein, Matthew Herper, and Angus ChenMay 29, 2026 Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.Matthew Herper[email protected]Matthew Herper covers medical innovation — both its promise and its perils.Angus Chen[email protected]Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community.

You can reach Angus on Signal at angus.08. You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here.

We’re ASCOmaxxing.Advertisement Rest assured, this will not require Adam Feuerstein, Matthew Herper or Angus Chen to hammer on their jawlines. They will, however, be scouring the ASCO annual meeting to bring you the cancer news, analysis and event coverage you crave. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In ASCO, biotechnology, Cancer, drug development, FDA, Pharmaceuticals, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology.

He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Matthew Herper Senior Writer, Medicine, Editorial Director of Events Matthew Herper covers medical innovation — both its promise and its perils.

Angus Chen Cancer Reporter Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08. Newsletter Critical updates on the fast-moving world of cancer research, treatment, and patient care Recommended Biotech June 1, 2026 STAT Plus: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns Biotech June 1, 2026 STAT Plus: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways Advertisement The Readout June 1, 2026 STAT Plus: A turning point for pancreatic cancer patients Biotech June 1, 2026 STAT Plus: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug Biotech May 31, 2026 STAT Plus: A standing ovation for RevMed, and caution for Akeso Subscriber Picks